26S proteasome beta 1 and beta 1i subunits (PSMB6 / PSMB9)

The 26S proteasome is a large, multi-subunit complex essential for the ATP-dependent degradation of ubiquitinated proteins, thereby regulating key cellular processes such as the cell cycle, signal transduction, and apoptosis [4, 9, 11]. The beta 1 (PSMB6) and beta 1i (PSMB9/LMP2) subunits are the catalytic components responsible for the "caspase-like" or "post-acidic" proteolytic activity of the proteasome, specifically cleaving peptide bonds after acidic residues [3, 6, 7, 14]. While beta 1 is a constitutive subunit found in most cells, beta 1i is an inducible subunit that replaces beta 1 in the immunoproteasome upon stimulation by pro-inflammatory cytokines like interferon-gamma [5, 10, 12, 19]. This substitution alters the repertoire of generated peptides to favor MHC class I antigen presentation, making these subunits critical for immune surveillance [7, 10, 18]. In clinical practice, broad-spectrum proteasome inhibitors like bortezomib target these subunits alongside the beta 5 subunit to treat hematologic malignancies such as multiple myeloma [2, 13, 19, 20]. More recently, selective inhibitors of the immunoproteasome subunits, including beta 1i, have entered clinical development for the treatment of autoimmune and inflammatory diseases, aiming to modulate immune responses with reduced systemic toxicity compared to constitutive proteasome inhibition [5, 10, 19].

Other names

Proteasome 20S subunit beta 6Proteasome 20S subunit beta 9LMP2PSMB6PSMB9Beta 1 subunitBeta 1i subunitCaspase-like subunitRING12Delta

Inhibition of the caspase-like proteolytic activity of the 26S proteasome and immunoproteasome.